Volume 184 - Issue 11
Are meal replacements an effective clinical tool for weight loss? — a clarification
Author: Garry J Egger
Med J Aust 2006; 184 (11): 591. || doi: 10.5694/j.1326-5377.2006.tb00399.x
Published online: 5 June 2006
Published online: 5 June 2006
To the Editor: I would like to clarify several issues relating to the competing interests statement for my editorial in the 16 January issue of the Journal.1
In my statement, I declared that I have used several meal replacement products in clinical settings and that I am not employed by, and do not receive benefit from, any companies producing these products.
By way of further information, I have used Optifast (Novartis) and Dr MacLeod’s (Orfam) products in clinical work in the past. These were always sold at cost to patients, or patients were referred to a chemist, so there was no direct financial benefit to me. I currently use KicStart (Pharmacy Health Solutions) as part of the kit for “Professor Trim’s weight loss program for men”. I purchase these in bulk at wholesale prices from the manufacturer and include them as part of the total program (which is much more than just meal replacement).
References
- Egger G. Are meal replacements an effective clinical tool for weight loss [editorial]? Med J Aust 2006; 184: 52-53. 0_GCFEIABD
Beyond Fibrosis Stratification: Integrating Behavioural, Metabolic and Policy-Level Interventions in Metabolic Dysfunction-Associated Steatotic Liver Disease
Yousef Hakimi, Prarthana Thiagarajan, Michael Braude
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
When ‘Liver Enzymes’ Are Not Hepatic: Late-Onset Pompe Disease
Shauna Madigan, Georgina England, Wayne Rankin
Fatty Liver Disease in Australia: A Narrative Review on the Epidemiology, Natural History, Prognostication and Management in People With Metabolic Dysfunction
Karl Vaz, Daniel Clayton-Chubb, William W. Kemp, Stuart K. Roberts, Ammar Majeed
The early implementation phase of the Omega‐3 Test‐and‐Treat Program for reducing the risk of preterm birth, South Australia, 2021–22: an implementation evaluation study
Karen P Best, Celine Northcott, Lucy A Simmonds, Philippa Middleton, Lisa N Yelland, Vanessa Moffa, Khoa Lam, Penelope Coates, Cornelia Späth, Carol WK Siu, Karen Glover, Rhiannon Smith, Robert Gibson, Maria Makrides
Cause‐specific mortality among Queensland people with cirrhosis, by cirrhosis aetiology and decompensation status, 2007–22: a retrospective cohort study
Vikas Bhasker, Jessica R Fong, Paul J Clark, Gunter F Hartel, Richard Skoien, James O’Beirne, Elizabeth E Powell, Patricia C Valery